Influence Of Concentrate Levels In Diet And Body Biotypes On Productive Variables Of Guzera Beef Cattle

The goal of this study was evaluate diets (50 or 80% of concentrate) and body biotypes (late or early) on performance, behavior, carcass condition, meat quality, and feed cost estimates in feedlot finishing Guzera beef cattle. Use of concentrates in the diet may improve performance and carcass fat scores in ruminant animals, but Guzera beef cattle may be more efficient in forage conversion, which directly influences the economic viability of the production system. We evaluated 32 non-castrated male Guzera beef cattle at 32±2 months of age. The experimental design was completely randomized with four treatments and six replicates in a 2 × 2 factorial design (2 diets × 2 body biotypes). Initial and final body weights were 459.4±31.2 kg and 566.7±40.8 kg, respectively. There was no change (P > 0.05) in dry matter intake, feed conversion, or daily weight gain when the concentrate in the diet was increased to 80%. Animals fed a diet with 80% of concentrate spent less time (P < 0.05) ruminating (17.8±6.3 vs. 6.3±2.7% of the assessed time). Body biotype did not alter the variables. The rise from 50 to 80% in the proportion of dietary concentrate increased carcass fat, with positive returns in the production process, even given the reduction in rumination, which can lead to poor welfare of animals consuming 80% of dietary concentrate. Body biotype did not affect the variables studied, but it is worth emphasizing that the age at slaughter of these animals probably influenced this result. Thus, selection of the best diet should be based on feeding cost, and in accordance with the cost estimated in this study, the diet with 80% of concentrate is the most suitable for feedlot finished Guzera beef cattle.3764305431

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362